New drug combo takes on deadly breast cancer in small trial
NCT ID NCT02876302
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study tests whether adding the drug ruxolitinib to standard chemotherapy can help treat triple-negative inflammatory breast cancer, a rare and aggressive form of breast cancer. About 23 adults with this diagnosis will receive the combination before surgery. The goal is to see if the drug can block a cancer-driving protein and improve the chance of having no cancer left at the time of surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BREAST CANCER (IBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States